SEC Form 4 · accession 0000899243-16-031997
Invuity, Inc. · IVTY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Eric W Roberts
Director
Period of report
Oct 17, 2016
Accepted (ET)
Oct 19, 2016 · 8:31 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001393020
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2,F3 | Oct 17, 2016 | S | 1,000 | $12.075 | D | 249,632 | I | See footnote |
| Common Stock | holding | — | — | — | 69,945 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The shares were sold pursuant to the Rule 10b5-1 trading plan entered into by Valence CDK SPV, L.P. ("Valence CDK") on December 1, 2015.
- F2This transaction was executed in multiple trades at prices ranging from $12.00 to $12.25. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F3The shares are held by Valence CDK. Valence Life Sciences GP II, LLC ("Valence") is the General Partner of Valence CDK. The Reporting Person is a Managing Member of Valence and disclaims beneficial ownership of the shares held by Valence CDK, except to the extent of his pecuniary interest therein.